Recent molecular genetic studies have revealed various mutations in the mitogen-activated protein kinase (MAPK) pathway, including BRAF and FGFR1, in low-grade neuroepithelial tumors (4–6); however, associations between genotypes and pathological findings remain unclear (5, 7, 8). The gene discussed is BRAF; the disease is neuroepithelial neoplasm.